{"id":"W2804105316","doi":"10.1016/s1470-2045(18)30292-4","title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1011,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Ottawa","funders":"Astex Pharmaceuticals; Novartis","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Hormone receptor; Endocrine system; Hormone therapy; Gynecology; Cancer; Hormone","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03244725651231038,"score_gpt":0.3715379082167767,"score_spread":0.3390906517044663,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}